SVB Leerink lifts Sanofi [SNY] price estimate. Who else is bullish?

Related

Share

Sanofi [NASDAQ: SNY] jumped around 0.99 points on Wednesday, while shares priced at $49.05 at the close of the session, up 2.06%. The company report on October 21, 2021 that FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma.

FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option.

Sanofi stock is now 0.95% up from its year-to-date (YTD) trading value. SNY Stock saw the intraday high of $49.52 and lowest of $48.92 per share. The company’s 52-week high price is 54.26, which means current price is +8.59% above from all time high which was touched on 06/14/21.

Compared to the average trading volume of 1.97M shares, SNY reached a trading volume of 3011649 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Sanofi [SNY]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNY shares is $63.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

SVB Leerink have made an estimate for Sanofi shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 27, 2021. The new note on the price target was released on January 15, 2021, representing the official price target for Sanofi stock.

The Average True Range (ATR) for Sanofi is set at 0.67, with the Price to Sales ratio for SNY stock in the period of the last 12 months amounting to 2.84. The Price to Book ratio for the last quarter was 1.67, with the Price to Cash per share for the same quarter was set at 4.47.

How has SNY stock performed recently?

Sanofi [SNY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.72. With this latest performance, SNY shares gained by 1.72% in over the last four-week period, additionally sinking by -5.78% over the last 6 months – not to mention a drop of -1.66% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNY stock in for the last two-week period is set at 52.81, with the RSI for the last a single of trading hit 58.08, and the three-weeks RSI is set at 49.49 for Sanofi [SNY]. The present Moving Average for the last 50 days of trading for this stock 49.79, while it was recorded at 48.52 for the last single week of trading, and 50.27 for the last 200 days.

Sanofi [SNY]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sanofi [SNY] shares currently have an operating margin of +20.18 and a Gross Margin at +61.28. Sanofi’s Net Margin is presently recorded at +34.17.

Return on Total Capital for SNY is now 8.46, given the latest momentum, and Return on Invested Capital for the company is 15.04. Return on Equity for this stock inclined to 20.20, with Return on Assets sitting at 10.84. When it comes to the capital structure of this company, Sanofi [SNY] has a Total Debt to Total Equity ratio set at 37.58. Additionally, SNY Total Debt to Total Capital is recorded at 27.31, with Total Debt to Total Assets ending up at 20.67. Long-Term Debt to Equity for the company is recorded at 32.82, with the Long-Term Debt to Total Capital now at 23.85.

Reflecting on the efficiency of the workforce at the company, Sanofi [SNY] managed to generate an average of $123,868 per employee. Receivables Turnover for the company is 3.60 with a Total Asset Turnover recorded at a value of 0.32.Sanofi’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.50.

Earnings analysis for Sanofi [SNY]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sanofi go to 7.50%.

Insider trade positions for Sanofi [SNY]

There are presently around $9,997 million, or 8.30% of SNY stock, in the hands of institutional investors. The top three institutional holders of SNY stocks are: DODGE & COX with ownership of 70,280,548, which is approximately 1.765% of the company’s market cap and around 16.40% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 17,885,092 shares of the stock with an approximate value of $877.26 million in SNY stocks shares; and FMR LLC, currently with $810.31 million in SNY stock with ownership of nearly 13.818% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Sanofi stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 281 institutional holders increased their position in Sanofi [NASDAQ:SNY] by around 11,907,022 shares. Additionally, 203 investors decreased positions by around 7,119,242 shares, while 125 investors held positions by with 184,795,791 shares. The mentioned changes placed institutional holdings at 203,822,055 shares, according to the latest SEC report filing. SNY stock had 53 new institutional investments in for a total of 3,074,337 shares, while 43 institutional investors sold positions of 769,377 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam